On Thursday, Realty Income Corp (NYSE:O)’s shares inclined 1.02% to $47.19.
Realty Income Corporation ( O), The Monthly Dividend Company®, declared that its Board of Directors has declared the 541st successive common stock monthly dividend. The dividend amount of $0.19 per share, representing an annualized amount of $2.28 per share, is payable on August 17, 2015 to shareholders of record as of August 3, 2015.
The Board of Directors also declared dividends on the company’s Monthly Income Class F preferred stock. The monthly dividend amount of $0.138021 on the Class F preferred shares is payable on August 17, 2015 to shareholders of record as of August 1, 2015. The annualized dividend amount for the Class F preferred shares is $1.65625 per share.
Realty Income Corporation is a publicly traded real estate investment trust. It invests in the real estate markets of the United States. The firm makes investments in commercial real estate. Realty Income Corporation was founded in 1969 and is based in Escondido, California.
Herbalife Ltd. (NYSE:HLF)’s shares gained 1.71% to $53.64.
Global nutrition company, Herbalife Ltd. (HLF), declared that it will release its financial results for the second quarter, ended June 30, 2015, after the close of trading on the NYSE on Wednesday, August 5, 2015. The same day, at 5:30 p.m. ET (2:30 p.m. PT), Herbalife’s senior administration team will host an investor conference call to talk about Herbalife’s recent financial results and provide an update on current business trends.
Herbalife Ltd., a nutrition company, develops and sells weight administration, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products. The company offers science-based products in four principal categories, counting weight administration; targeted nutrition; energy, sports, and fitness; and outer nutrition. The weight administration product portfolio comprises meal replacement, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. The targeted nutrition products comprise dietary and nutritional supplements containing herbs, vitamins, minerals, and other natural ingredients.
At the end of Thursday’s trade, American Apparel Inc (NYSEMKT:APP)‘s shares dipped -4.54% to $0.334.
American Apparel, Inc. (APP), a vertically-integrated manufacturer, distributor, and retailer of branded fashion-basic apparel, recently declared another leadership appointment. Brian McHale has been named Senior Vice President and Chief Information Officer.
As Chief Information Officer, McHale will oversee information technology and computer systems at the company. In addition to providing critical support to American Apparel’s onsite hardware and software applications, McHale will also lead the development and expansion of the company’s retail digital capabilities alongside Thoryn Stephens, recently designated Chief Digital Officer.
McHale comes to American Apparel with over 25 years of experience developing IT governance, Business Intelligence and Big Data solutions for some of the U.S.’s largest companies such as DirecTV and Verizon. He has also transformed these companies to cloud-based infrastructures, driving efficiencies and cost savings. McHale’s experience comprises work for agency clients in a variety of categories, counting turnaround businesses, similar to American Apparel.
McHale assumed his role on April 13, 2015, and reports directly to Chief Financial Officer Hassan Natha.
American Apparel, Inc. designs, manufactures, distributes, retails, and sells branded fashion basic apparel products, and clothing and accessories for women, men, children, and babies. It offers T-shirts, denim, sweaters, jackets, and accessories. The company sells its products through the wholesale distribution channel, counting supplying T-shirts and other casual wear to distributors and screen printers; direct to customers through its retail stores; and through an online retail e-commerce Website, americanapparel.com.
Cempra Inc (NASDAQ:CEMP), ended its Thursday’s trading session with 6.39% gain, and closed at $41.48.
Cempra, Inc. (CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, recently declared the completion of enrollment for the global Solitaire-IV Phase 3 trial of solithromycin in adult patients with moderate to moderately severe community-attained bacterial pneumonia (CABP). Top-line efficacy and safety data from this study are predictable to be declared by the end of the year.
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates comprise solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community attained bacterial pneumonia, in addition to for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has accomplished Phase II clinical trials for refractory bone and joint infections.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
